A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
Atish D ChoudhuryKathryn P GrayJeffrey G SupkoLauren C HarshmanMary-Ellen TaplinAmanda F PaceMatthew FarinaKatherine A ZukotynskiBrandon BernardPhilip W KantoffMark PomerantzChristopher SweeneyPublished in: The Prostate (2018)
Based on tolerability and preliminary efficacy, 40 mg cabozantinib plus 1000 mg abiraterone daily is the RP2D.